When to Refer Diabetic Patients for Retina Care
Schedule Today
Who Is Affected and What Increases Risk
Diabetic retinopathy is widespread among people living with diabetes, and certain factors can significantly increase a person's risk of developing it or experiencing rapid progression. Identifying these risk factors helps determine which patients need earlier or more frequent screening.
A meaningful portion of people with diabetes have some form of diabetic retinopathy, and a smaller but significant group have the vision-threatening form of the disease. The number of Americans affected is expected to grow substantially in the coming decades as diabetes rates continue to rise. Early identification and referral remain the best tools for reducing vision loss at a population level.
Several factors increase the likelihood that a person with diabetes will develop retinopathy or experience faster progression. Being aware of these can help identify patients who need closer monitoring.
- Long duration of diabetes, particularly fifteen years or more
- Chronic high blood sugar, also called poor glycemic control
- High blood pressure, also called hypertension
- High cholesterol and other lipid abnormalities, called dyslipidemia
- Kidney disease, also called nephropathy
Patients who have had diabetes for many years are at significantly higher risk of developing severe retinopathy compared to those recently diagnosed, even if their current blood sugar appears controlled.
Pregnant women with pre-existing diabetes face an increased risk of rapid retinopathy progression and should receive a dilated eye exam early in pregnancy, with close monitoring throughout. Women who develop gestational diabetes (diabetes that begins during pregnancy) do not require a separate eye exam specifically for that condition.
Adolescents going through puberty may also experience accelerated progression of retinopathy and benefit from closer follow-up. Additionally, nearly one in four people newly diagnosed with diabetes may already have early signs of retinopathy at the time of diagnosis, making initial screening at the point of diagnosis essential.
Newer glucose-lowering medications, including semaglutide and similar agents, can produce rapid improvements in blood sugar control. In some patients, especially those with previously uncontrolled diabetes, this rapid change may accelerate the onset or progression of diabetic retinopathy. Patients starting these treatments may benefit from a baseline retinal evaluation and closer monitoring during the first year of therapy.
Signs and Symptoms
One of the most challenging aspects of diabetic retinopathy is that it often causes no symptoms in its early stages. By the time a patient notices changes in their vision, the disease may already be advanced. This makes routine screening critical for every person with diabetes.
Many patients feel their vision is perfectly normal even when significant retinal changes are already present. Damage to retinal blood vessels can accumulate slowly and without pain. This is why the absence of symptoms is never a reliable indicator that the retina is healthy in a person living with diabetes.
As diabetic retinopathy progresses, patients may begin to notice blurred or fluctuating vision, dark spots or floaters, difficulty seeing in low light, and faded or washed-out colors. If diabetic macular edema develops, patients may notice that straight lines appear wavy or that reading becomes increasingly difficult.
Certain symptoms indicate a serious problem that requires immediate evaluation. A sudden increase in floaters, flashes of light, a shadow or dark curtain across part of the visual field, or sudden vision loss in one eye are all warning signs that should not be ignored. These can indicate a vitreous hemorrhage (bleeding inside the eye) or a retinal detachment, both of which require prompt treatment to protect vision.
Treatment Options
Effective treatments are available for diabetic retinopathy and diabetic macular edema. The right approach depends on the stage of the disease, the presence of macular swelling, and the patient's overall health. A retina specialist will develop an individualized plan for each patient.
Anti-VEGF medications are the primary treatment for center-involved diabetic macular edema with vision loss and for proliferative diabetic retinopathy. These medications block vascular endothelial growth factor, the protein that drives abnormal blood vessel growth and leakage. They are delivered as intravitreal injections, meaning they are injected directly into the eye in a clinical setting.
Several anti-VEGF agents are used in retina care. Aflibercept (Eylea) is commonly used, typically given every four to eight weeks after initial loading doses. High-dose aflibercept (Eylea HD) is approved for dosing intervals of up to five months for DME. Faricimab (Vabysmo) is a bispecific antibody that targets both VEGF and angiopoietin-2, and can be given as infrequently as every sixteen weeks for some patients. Ranibizumab (Lucentis) was one of the first anti-VEGF agents approved for eye use and is typically given every four weeks.
Bevacizumab (Avastin) is FDA-approved for certain cancers but is widely used off-label by retina specialists for diabetic macular edema and diabetic retinopathy. It works through the same VEGF-blocking mechanism as the other agents in this class and is typically given every four to six weeks. Patients should be informed that its use for eye conditions is off-label.
Ranibizumab injection 100 mg/mL (Susvimo) is the first FDA-approved continuous delivery option for diabetic retinopathy. A small refillable implant is surgically placed in the eye and delivers medication continuously, with refills needed approximately every nine months. This may be an appropriate option for patients who face challenges with frequent office visits.
Panretinal photocoagulation, or PRP, is a laser treatment that remains an important option for proliferative diabetic retinopathy. During PRP, a retina specialist applies a pattern of small laser spots to the peripheral retina, reducing its oxygen demand and slowing the growth of abnormal blood vessels. Focal or grid laser therapy may also be used in selected cases of diabetic macular edema.
Vitrectomy, a surgery to remove the gel inside the eye called the vitreous, may be necessary when there is significant bleeding into the vitreous or when scar tissue pulls on the retina and threatens to cause or has already caused detachment. During the procedure, the retina specialist removes the vitreous along with any blood or scar tissue and replaces it with a clear solution or gas bubble to support healing.
What to Expect During Treatment
Understanding what treatment involves can help patients feel more prepared and more likely to follow through with their care plan. Most patients find that treatment is manageable and that any discomfort is brief.
When diabetic retinopathy is detected and treated early, current treatment strategies can be highly effective at preventing severe vision loss. Anti-VEGF injections can reduce the severity of the disease and, in some patients, lead to measurable improvement on imaging. However, outcomes depend significantly on how advanced the disease is when treatment begins, which is why early referral matters.
Most anti-VEGF treatment visits take less than an hour from start to finish. Before the injection, the eye is numbed with anesthetic drops to minimize discomfort. Patients may notice mild soreness, redness, or a gritty sensation after the injection, but these effects typically resolve within a day or two. While the idea of an eye injection may feel daunting, most patients find the experience far more manageable than they anticipated.
Diabetic retinopathy is a chronic condition that requires long-term management. Even after successful treatment, regular follow-up exams are essential to monitor for recurrence or progression. A retina specialist will determine the appropriate follow-up schedule based on the severity of the disease and how well the patient is responding to treatment.
Living with Diabetic Retinopathy
Managing diabetic retinopathy goes beyond what happens in the clinic. Patients who take an active role in their overall health and stay consistent with their appointments have the best chance of protecting their vision over the long term.
Controlling blood sugar is one of the most powerful steps a person can take to slow retinopathy progression. Working with a primary care provider or endocrinologist to maintain healthy blood sugar, blood pressure, and cholesterol levels supports the health of retinal blood vessels. These efforts complement the treatments provided by a retina specialist and can reduce the need for more intensive interventions over time.
Keeping all scheduled eye appointments is critical. Because diabetic retinopathy can worsen without producing symptoms, delaying or skipping visits can allow the disease to reach a stage where treatment is less effective. Patients who notice any new changes in their vision between appointments should contact a retina specialist promptly, rather than waiting until their next scheduled visit.
A diagnosis of diabetic retinopathy can cause significant worry. Patients may benefit from connecting with diabetes support groups or low-vision rehabilitation services if their sight has already been affected. Staying informed about the condition and actively participating in treatment decisions can help patients feel more confident and less overwhelmed by the road ahead.
When to Refer to a Retina Specialist
Primary care providers and optometrists play an essential role in identifying patients who need retina care. Knowing which findings require referral, and how urgently, allows for timely intervention before vision loss occurs.
Certain clinical findings during a screening exam should prompt referral to a retina specialist. These include the following.
- Any level of macular edema detected on exam or imaging
- Severe nonproliferative diabetic retinopathy, which is a precursor to the proliferative stage
- Any proliferative diabetic retinopathy, including the presence of new abnormal blood vessels
- Visual acuity worse than 20/40 or patient-reported symptomatic vision changes
- Neovascularization of the iris or angle, meaning new blood vessel growth in the front of the eye, which requires urgent referral
Not all referrals carry the same level of urgency. High-risk proliferative diabetic retinopathy, defined by larger areas of new vessel growth on the optic disc or any new vessel growth accompanied by bleeding, should be referred within 24 to 48 hours. Lower-risk proliferative disease may be referred within two to four weeks. Patients with neovascularization of the anterior segment (new vessel growth in the front part of the eye) should be seen urgently, as prompt treatment can help prevent severe complications such as neovascular glaucoma.
Certain patients benefit from retinal evaluations that go beyond the standard annual schedule. These include pregnant women with pre-existing diabetes, adolescents going through puberty, patients beginning rapid glucose-lowering therapies such as semaglutide, and anyone with a long history of diabetes or chronically poor blood sugar control. When clinical uncertainty exists, referring to a retina specialist for a baseline evaluation is always a reasonable and proactive decision.
Frequently Asked Questions
The following questions address common concerns and practical decisions that patients and referring providers often raise about diabetic retinopathy.
Yes, and this is one of the most important points to understand. Significant retinal changes can occur and progress without any noticeable effect on vision. A person may feel they can see clearly while the blood vessels in their retina are already being damaged. This is why keeping annual dilated eye exams is non-negotiable for anyone with diabetes, regardless of how well they feel they can see.
The rate of progression varies widely between individuals. Some people remain at a mild stage for many years, while others advance to a vision-threatening stage within months, particularly if blood sugar, blood pressure, or cholesterol are poorly managed. Pregnancy, puberty, and rapid changes in blood sugar control can all accelerate this process. The unpredictability of progression is itself a reason to stay on schedule with monitoring rather than assuming stability.
Absolutely. Retina treatment addresses what is happening inside the eye, but it does not replace systemic diabetes management. A retina specialist and a primary care provider or endocrinologist work in complementary roles. Improving blood sugar, blood pressure, and cholesterol control can slow retinopathy progression and reduce the frequency and intensity of eye treatments needed over time.
Untreated diabetic retinopathy can lead to permanent and severe vision loss. Proliferative disease can cause bleeding inside the eye, scar tissue formation, and retinal detachment. Diabetic macular edema can destroy the central vision needed for reading, recognizing faces, and driving. Early detection and prompt referral to a retina specialist offer the best chance of maintaining functional vision over the long term.
There is growing clinical evidence that rapid blood sugar improvement, including from medications such as semaglutide, may worsen or trigger diabetic retinopathy in some patients, particularly those who previously had poor glycemic control. A retina specialist may recommend a baseline evaluation before starting these medications and more frequent follow-up during the first year of treatment. Patients and their prescribing providers should discuss this risk proactively rather than waiting until symptoms appear.